PLUS1
Best deals to access real time data! |
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
CHART Trader
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Immunic Inc | IMUX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.4319 | 4.9% | 9.2519 | 9.4928 | 9.1701 | 9.31 | 8.82 | 09:48:15 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 9.19 | 9.48 | 0.29 | 3.06% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 83 | 14,208 | $ 9.33 | $ 132,507 | 13,123 | 6.20 - 22.6626 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:48:15 | 200 | $ 9.2519 | USD |
Immunic Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 93.60M | 10.12M | $ -41.48M | -39.20 | - | 9.78M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 2.00 | 3.30% |
Immunic News
| Date | Time | Source | News Article |
|---|---|---|---|
| 12/06/2019 | 16:41 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 12/04/2019 | 07:01 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 12/04/2019 | 06:30 | PR Newswire (US) | Immunic, Inc. to Present Data on IMU-856, for the First.. |
| 11/25/2019 | 06:30 | PR Newswire (US) | Immunic, Inc. to Participate in Investor and Scientific.. |
| 11/19/2019 | 17:53 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 11/19/2019 | 17:51 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
| 11/19/2019 | 07:00 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IMUX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.73 | 9.4928 | 6.73 | 8.48 | 35,932 | 2.52 | 37.47% |
| 1 Month | 7.98 | 9.4928 | 6.20 | 7.55 | 22,985 | 1.27 | 15.94% |
| 3 Months | 14.59 | 15.00 | 6.20 | 9.46 | 22,211 | -5.34 | -36.59% |
| 6 Months | 9.06 | 19.05 | 6.20 | 13.50 | 83,665 | 0.1919 | 2.12% |
| 1 Year | 22.00 | 22.6626 | 6.20 | 13.56 | 87,676 | -12.75 | -57.95% |
| 3 Years | 22.00 | 22.6626 | 6.20 | 13.56 | 87,676 | -12.75 | -57.95% |
| 5 Years | 22.00 | 22.6626 | 6.20 | 13.56 | 87,676 | -12.75 | -57.95% |
Immunic Description
| Immunic Inc is a clinical stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, IMU-935 is an inverse agonist of RORyt and IMU-856 targets the restoration of the intestinal barrier function. |
